Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA.
Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA.
Hematol Oncol Stem Cell Ther. 2021 Jun;14(2):95-103. doi: 10.1016/j.hemonc.2020.05.011. Epub 2020 Jun 17.
Hodgkin lymphoma (HL) is a highly responsive disease with nearly 70% of patients experiencing cure after front-line chemotherapy. Patients who experience disease relapse receive salvage chemotherapy followed by consolidation with autologous hematopoietic cell transplantation (auto-HCT). Nearly 50% of patients relapse after an auto-HCT and constitute a subgroup with poor prognosis. Novel treatments such as immune checkpoint inhibitors and an anti-CD30 monoclonal antibody are currently approved for patients relapsing after auto-HCT; however, the duration of remission with these therapies remains limited. Allogeneic HCT is currently the only potentially curative treatment modality for patients relapsing after a prior auto-HCT. Early clinical trials with chimeric antigen receptor T-cell therapy targeting CD30 are underway for patients with relapsed/refractory HL and are already demonstrating safety and promising efficacy.
霍奇金淋巴瘤（HL）是一种高度敏感的疾病，近 70%的患者在一线化疗后获得治愈。经历疾病复发的患者接受挽救性化疗，随后进行自体造血细胞移植（auto-HCT）巩固治疗。近 50%的患者在接受 auto-HCT 后复发，构成预后不良的亚组。免疫检查点抑制剂和抗 CD30 单克隆抗体等新型治疗方法目前已获批用于 auto-HCT 后复发的患者；然而，这些治疗方法的缓解持续时间仍然有限。异基因 HCT 目前是既往接受 auto-HCT 后复发患者唯一潜在的治愈治疗方式。针对复发/难治性 HL 患者的嵌合抗原受体 T 细胞疗法的早期临床试验正在进行中，已经显示出安全性和有前景的疗效。
